ArticleSubstance abuse2018
Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program.
Article in Substance abuse, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Coordinating Systems of Care for HIV and Opioid Use Disorder: A Systematic Review of Enablers and Barriers to Integrated Service Access, and Systems and Tools Required for Implementation.Medical care research and review : MCRR · 2022Pooled it
- "It was good because they have a relationship with us": A qualitative study on low-threshold buprenorphine treatment at syringe services programs.Journal of substance use and addiction treatment · 2026Trial
- Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.Harm reduction journal · 2024Trial
- Participant perceptions on the acceptability and feasibility of a telemedicine-based HIV PrEP and buprenorphine/naloxone program embedded within syringe services programs: a qualitative descriptive evaluation.Harm reduction journal · 2022Trial
- Operationalizing recipient-centeredness: three facets of values-driven care in syringe services programs.Implementation science communications · 2026Article
- Interest in contingency management and reducing stimulant use among syringe service program participants.Journal of substance use and addiction treatment · 2025Article
- A call for upstream solutions to the unregulated drug crisis in British Columbia, Canada: Locked up or locked out.Canadian journal of public health = Revue canadienne de sante publique · 2025Article
- Exploring barriers and potential solutions before implementing a scale-up strategy to expand methadone coverage among people who inject drugs in Tajikistan.Journal of substance use and addiction treatment · 2025Article
- "It always needs a higher level of care than what I can provide": Practical, ethical, and administrative tensions arising from the integration of wound care services into syringe service programs in Maryland.The International journal on drug policy · 2025Article
- Patient experiences of buprenorphine dispensing from a mobile medical unit.Addiction science & clinical practice · 2024Article
- Posttraumatic stress disorder in people who use drugs: syringe services program utilization, treatment need, and preferences for onsite mental health care.Harm reduction journal · 2024Article
- Project CHARIOT: study protocol for a hybrid type 1 effectiveness-implementation study of comprehensive tele-harm reduction for engagement of people who inject drugs in HIV prevention services.Addiction science & clinical practice · 2024Article
- Community-based substance use treatment programs for reentering justice-involved adults: A scoping review.Drug and alcohol dependence reports · 2024Article
- Adaptation of the Tele-Harm Reduction intervention to promote initiation and retention in buprenorphine treatment among people who inject drugs: a retrospective cohort study.Annals of medicine · 2023Article
- Availability of telehealth-based services at syringe services programs under the COVID-19 Public Health Emergency.Harm reduction journal · 2023Article
- "Come try it out. Get your foot in the door:" Exploring patient perspectives on low-barrier treatment for opioid use disorder.Drug and alcohol dependence · 2023Article
- Outcomes of a mobile medical unit for low-threshold buprenorphine access targeting opioid overdose hot spots in Chicago.Journal of substance use and addiction treatment · 2023Article
- Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature.Addiction science & clinical practice · 2023Article
- Descriptive study: the novel "full spectrum people-with-opioid-use-disorder care model".Harm reduction journal · 2023Article
- Sorting through life: evaluating patient-important measures of success in a medication for opioid use disorder (MOUD) treatment program.Substance abuse treatment, prevention, and policy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundSyringe exchange programs are uniquely positioned to offer treatment services to interested clients. Prevention Point Philadelphia recently expanded to offer buprenorphine maintenance treatment through its Stabilization, Treatment, and Engagement Program (STEP).
objectiveTo describe the STEP model of care and report treatment outcomes.
methodsRetrospective chart review of patients enrolled in STEP (October 2011-August 2014). Our main outcome measure was time retained in treatment, defined as time from treatment initiation to treatment failure. Secondary outcome measures were buprenorphine and opiate use, from urine toxicology screens. We analyzed retention in treatment using Kaplan-Meier survival estimates; patients who remained in treatment at the end of the study period were censored on that day. For buprenorphine and opiate use, we calculated the percentage of patients who were positive for buprenorphine and opiates in each month of treatment.
resultsOf the 124 patients enrolled in STEP, the median age was 41 (range 21 to 63) and 80% reported injection heroin use. Comorbidities were common: 33% had HIV infection, most reported anxiety (78%) or depression (71%), and 20% were homeless. The most common program outcomes were unplanned self-discharge (n = 29; 23%), incarceration (n = 20; 16%), and administrative discharge (n = 19; 15%). The percentage of patients retained in treatment at 3, 6, 9, and 12 months was 77%, 65%, 59%, and 56%, respectively. Among those retained, the percentage with a positive buprenorphine screen at 3, 6, 9, and 12 months was 88%, 100%, 96%, and 95%, respectively. The percentage with a positive opiates screen was 19%, 13%, 17%, and 16%, respectively.
conclusionsWith a program that blended organizational and community resources, retention in buprenorphine maintenance treatment was comparable to retention rates reported from other settings. Further research should directly compare treatment outcomes in syringe exchange program-based settings versus primary care and specialty settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.